子宫腺肌症患者辅助生殖后活产率降低:一项匹配对照研究
这项观察性研究纳入2018年1月1日至2022年12月31日接受IVF/ICSI全胚冷冻策略的18-42岁女性,285例子宫腺肌症患者按年龄、冷冻囊胚数和优质囊胚数与285例对照1:1匹配。子宫腺肌症组累积活产率显著低于对照组(41.4% vs 51.9%;OR=0.65,95%CI[0.47-0.91];P=0.012),临床妊娠率亦降低(53.3% vs 63.9%;P=0.011),早期流产率无显著差异;多因素分析显示子宫腺肌症是活产率降低的独立危险因素(OR=0.7,95%CI[0.4-0.9])。
要点
- 子宫腺肌症患者IVF/ICSI后累积活产率较匹配对照降低(41.4% vs 51.9%;OR=0.65,95%CI[0.47-0.91])。
- 临床妊娠率亦降低(53.3% vs 63.9%;P=0.011),早期流产率无显著差异。
- 多因素分析显示子宫腺肌症是活产率降低的独立危险因素(OR=0.7,95%CI[0.4-0.9])。
核心结论
- 子宫腺肌症与辅助生殖治疗后活产率降低相关。
研究设计与样本
- 观察性研究,纳入2018年1月1日至2022年12月31日接受IVF/ICSI全胚冷冻策略的18-42岁女性,每例至少有一个可移植囊胚。
- 子宫腺肌症组为经盆腔MRI由妇科放射科医师确诊的患者,对照组为无子宫腺肌症的特发性、输卵管和/或男性因素不孕女性。
- 共纳入285例子宫腺肌症患者,按年龄、冷冻囊胚数和优质囊胚数与对照1:1匹配。
主要发现
- 子宫腺肌症组与对照组平均年龄分别为35.4±3.3岁和35.5±3.4岁,平均冷冻囊胚数分别为3.5±2.5和3.6±2.6,平均优质囊胚数分别为0.4±0.7和0.4±0.5。
- 子宫腺肌症组MRI显示内弥漫性子宫腺肌症占73.7%,腺肌瘤占3.5%,外源性子宫腺肌症病灶占46.7%。
- 累积活产率子宫腺肌症组显著低于对照组(41.4% vs 51.9%;OR=0.65,95%CI[0.47-0.91];P=0.012)。
- 临床妊娠率子宫腺肌症组低于对照组(53.3% vs 63.9%;P=0.011),早期流产率两组无显著差异。
- 多因素分析校正全胚冷冻指征、AMH水平、BMI、不孕类型和ART方案(IVF vs ICSI)后,子宫腺肌症是活产率降低的独立危险因素(OR=0.7,95%CI[0.4-0.9])。
临床怎么用
- 作者认为,对于不孕女性,医生进行全面临床和影像评估以发现子宫腺肌症至关重要。
局限性
- 本研究患者来自专注于子宫内膜异位症和子宫腺肌症管理的专科转诊中心,可能引入选择偏倚,因为这些女性可能为更严重类型的子宫腺肌症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: How does adenomyosis affect live birth rates (LBRs) in women undergoing ART compared to a matched control population? SUMMARY ANSWER: Women with adenomyosis, matched with controls for age, blastocyst count, and top-quality blastocyst count, exhibited reduced LBR following IVF/ICSI treatment. WHAT IS KNOWN ALREADY: Adenomyosis, a benign uterine disorder, is believed to hinder implantation due to anatomical, hormonal, and immune disruptions. Its precise impact on LBRs following ART, however, remains controversial, with studies presenting inconsistent outcomes. It is uncertain whether adenomyosis directly reduces ART success or if confounding factors such as age or embryo quality play a more significant role. STUDY DESIGN, SIZE, DURATION: This observational study included women aged 18-42 years undergoing IVF/ICSI treatments with a freeze-all strategy from 1 January 2018 to 31 December 2022, each having at least one available blastocyst for transfer. The adenomyosis group consisted of patients with a confirmed diagnosis through pelvic MRI, interpreted by gynecologic radiologists. The control group included women without adenomyosis, who had idiopathic, tubal, and/or male factor infertility. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 285 women with adenomyosis were included. These patients were matched 1:1 with controls based on age, the number of cryopreserved blastocysts, and the number of top-quality blastocysts. The primary outcome was the cumulative LBR per patient following a single oocyte retrieval, with secondary outcomes including clinical pregnancy rate (CPR) and early miscarriage rate (EMR). Both univariate and multivariate analyses were conducted. MAIN RESULTS AND THE ROLE OF CHANCE: In this study, 285 women with adenomyosis were matched with 285 controls. The mean age was 35.4 ± 3.3 and 35.5 ± 3.4 years, respectively, with an average of 3.5 ± 2.5 and 3.6 ± 2.6 cryopreserved blastocysts and 0.4 ± 0.7 and 0.4 ± 0.5 top-quality blastocysts, respectively. In the adenomyosis group, MRI revealed internal diffuse adenomyosis in 73.7% of patients, adenomyoma in 3.5%, and external adenomyosis lesions in 46.7%. The cumulative LBR was significantly lower in the adenomyosis group compared to controls (41.4% versus 51.9%; odds ratio = 0.65, 95% CI [0.47-0.91]; P = 0.012). Similarly, the CPR was reduced in the adenomyosis group (53.3% versus 63.9%; P = 0.011). No significant difference was found in the EMR. Multivariate analysis, adjusted for confounders such as freeze-all indication, AMH levels, BMI, infertility type, and ART procedure (IVF versus ICSI), identified adenomyosis as an independent risk factor for reduced LBR (OR = 0.7, 95% CI [0.4-0.9]). These findings indicate that adenomyosis is associated with lower ART success rates. LIMITATIONS, REASONS FOR CAUTION: Patients included in this study were from a specialized referral center focusing on the management of endometriosis and adenomyosis, potentially introducing selection bias, as these women may have more severe forms of adenomyosis. WIDER IMPLICATIONS OF THE FINDINGS: For infertile women, it is crucial for practitioners to conduct comprehensive clinical and imaging assessments to detect adenomyosis. Continued research is needed to refine and personalize ART management strategies for patients affected by this condition. STUDY FUNDING/COMPETING INTEREST(S): No external funding was received. P.V. is the co-editor-in-chief of the Journal of Endometriosis and Uterine Disorders. C.M. has received payments to her institution from Merck, Ferring, Theramex, Gedeon Richer, and Besins, as well as direct payments to her from Gedeon Richter and Ferring and honoraria from Merck Serono, Ferring, Besins, IBSA, and Organon and meeting/travel support but no payment from Ferring, Besins, and Gedeon Richter. C.C. has received grants from Merck, Ferring, Theramex, Gedeon Richter, and Besins, which were paid to his institution, and honoraria from Merck, Besins, Gedeon Richter, and Theramex, which he received directly. He has also received support for attending meetings from Besins, Gedeon Richter, and Merck but no payment. He is a founder and past-president of the Society for Endometriosis and Uterine Disorders (SEUD), an unpaid role. P.S. received grants or contracts from Merck, Ferring, Theramex, Gedeon Richter, Besins, paid to his institution, and direct payment to him for presentations and lectures from Merck, Ferring, Besins, Gedeon Richter, Theramex, IBSA, and General Electric Medical Systems. He also received travel support but no payment from Merck, Ferring, Besins, Gedeon Richter, Theramex, and IBSA. P.S. is a board member of the SEUD and an editorial board member of RBMO and GOF. C.P. has received payment for lectures and presentations from Ferring and support but no payment for attending meetings from Ferring. M.B. has received grants from Merck, Ferring, Theramex, Gedeon Richter, and Besins, which were paid to her institution, and direct payment from Merck, Ferring, Gedeon Richter, Theramex, IBSA, and Organon for lectures/presentations. She has also received support but not payment for attending meetings from Ferring and Gedeon Richter. TRIAL REGISTRATION NUMBER: Not applicable.
引用
- Bourdon M, Mimouni A, Maignien C, et al. Reduced live birth rates following ART in adenomyosis patients: a matched control study. Hum Reprod. 2025. PMID: 40159349. doi:10.1093/humrep/deaf052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。